OncoPep, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.oncopep.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Phase 2 Study to Evaluate PVX-410 + Pembrolizumab + Chemotherapy for Metastatic, PD-L1+ Triple-Negative Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Metastatic Triple-Negative Breast Carcinoma
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- OncoPep, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT04634747
Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma
Phase 1
Completed
- Conditions
- Smoldering Multiple Myeloma
- First Posted Date
- 2012-10-31
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- OncoPep, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01718899
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Illinois Cancer Specialists, Niles, Illinois, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
News
No news found